Laboratoire Dielen, 50110 Cherbourg-en-Cotentin, France.
Euraxi Pharma, 37300 Joué-lès-Tours, France.
Nutrients. 2022 Jun 10;14(12):2425. doi: 10.3390/nu14122425.
Anxiety is a high frequency disorder in the general population. It is usually treated with benzodiazepines, which cause side effects and a dependence that could make withdrawal difficult. Alternative treatments are therefore needed to reduce the use of anxiolytics, particularly for adjustment disorder with anxiety. An observational, multicentre, prospective, longitudinal study has been conducted by general practitioners and one gynaecologist to evaluate the efficacy of a dietary supplement on adjustment disorder with anxiety (Stress 2 study). Patients diagnosed as anxious with a score of ≥20 on the Hamilton Anxiety Rating Scale (Ham-A, first visit on Day 0 (V0)) were offered a 28-day treatment with a dietary supplement formulated with bioactive peptides from a fish protein hydrolysate (Gabolysat®), magnesium and vitamin B6. At the second visit (V1), the Ham-A Rating Scale, the Patient Global Impression scale (PGI) and the Clinical Global Impressions scale (CGI) were administered. A 50% reduction in the Ham-A score, was achieved for 41.9% of the patients. The mean Ham-A score decreased by 12.1 ± 5.7 points (p < 0.001) between V0 (25.6 ± 3.8) and V1 (13.6 ± 6.0). Furthermore, according to the CGI scale, the anxiety of 75.3% of patients improved significantly and very significantly, with limited side effects and a negligible rebound effect. In conclusion, adjustment disorder with anxiety seems to be effectively managed by an alternative and safer solution than benzodiazepines.
焦虑症是一种在普通人群中发病率较高的疾病。目前,通常使用苯二氮䓬类药物治疗,但此类药物会产生副作用和依赖性,导致戒断困难。因此,需要寻求替代治疗方法来减少苯二氮䓬类药物的使用,尤其是对于焦虑障碍的治疗。本研究由全科医生和一名妇科医生开展,为观察性、多中心、前瞻性、纵向研究,旨在评估一种膳食补充剂治疗焦虑障碍的疗效(Stress 2 研究)。入选标准为汉密尔顿焦虑量表(Ham-A)评分≥20 分的焦虑患者(第一次就诊,第 0 天[V0]),并接受为期 28 天的治疗,治疗方案为服用一种含有鱼蛋白水解物生物活性肽、镁和维生素 B6 的膳食补充剂(Gabolysat®)。在第二次就诊(V1)时,采用 Ham-A 评分量表、患者总体印象量表(PGI)和临床总体印象量表(CGI)对患者进行评估。41.9%的患者 Ham-A 评分降低≥50%。Ham-A 评分从 V0(25.6 ± 3.8)降低至 V1(13.6 ± 6.0),平均降低 12.1 ± 5.7 分(p < 0.001)。此外,根据 CGI 量表,75.3%的患者焦虑症状明显改善甚至显著改善,且不良反应有限,无明显反弹现象。综上,与苯二氮䓬类药物相比,该替代疗法治疗焦虑障碍的疗效相当,且安全性更高。